StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
June 30, 2026 6:44 AM
H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
